PGI25 Chronic Hepatitis C (CHC) Related Flu-like Symptoms; Development of a Patient Report Outcome (PRO) Measure and Results from Pilot Efficacy Studies  by Mathias, S.D. et al.
on therapy used more health care resources and were more costly during the
12-month observation period.
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OBJECTIVES: Proton pump inhibitors (PPIs) are the treatment of choice for gastro-
esophageal reflux disease (GERD), yet many patients experience persistent symp-
toms. To date, the burden of illness (BoI) among partial responders to PPI treatment
is not well understood. METHODS: REMAIN-France was a multicentre, 12-month
prospective study of adults with GERD who were newly identified as partial re-
sponders to optimised PPI treatment. BoI was evaluated at baseline, 3, 6, 9 and 12
months via patient-completed questionnaires, including the Reflux Symptom
Questionnaire with 7-day recall (RESQ-7). Medical evaluations were completed at
baseline, 6 and 12 months. Healthcare consumption was evaluated in terms of
visits to a primary care physician (PCP) and gastroenterologist, number of endos-
copies and days on prescribed GERD medication. All analyses were descriptive.
RESULTS: A total of 262 patients were enrolled (mean age, 54y; 40.5% men), the
majority of whom (n226, 86%) completed the 12-month study. Using the RESQ-7
questionnaire, 32% of patients reported severe symptoms and 48% reported daily
symptoms at baseline despite PPI treatment. Whilst continuing to receive pre-
scribed GERD medication (most commonly daily PPIs), symptoms remained bur-
densome at 6 and 12 months and indicated a positive relationship with impaired
quality of life (SF-36, EQ-5D) and decreased work productivity (WPAI-GERD). Be-
tween baseline and 6 months, the mean number of visits to a PCP and gastroen-
terologist among all patients was 1.9 and 0.5, respectively. For 7-12 months’ follow
up the corresponding figures were 1.8 and 0.4, respectively. A total of 12 patients
(4.6%) underwent endoscopy in the first 6 months of follow-up; thereafter, 10 pa-
tients (3.9%) underwent endoscopy between 7 and 12 months. CONCLUSIONS: In
French patients with GERD who have persistent symptoms despite PPI therapy, the
symptom burden is substantial and a positive relationship with impaired quality of
life and decreased work productivity is indicated. Supported by AstraZeneca R&D,
Mölndal, Sweden.
PGI25
CHRONIC HEPATITIS C (CHC) RELATED FLU-LIKE SYMPTOMS; DEVELOPMENT
OF A PATIENT REPORT OUTCOME (PRO) MEASURE AND RESULTS FROM PILOT
EFFICACY STUDIES
Mathias SD1, Crosby R1, Bayliss MS2, Hillson J3, Horga MA4, L’Italien G5, Sapra S6
1Health Outcomes Solutions, Winter Park, FL, USA, 2QualityMetric Incorporated, Lincoln, RI,
USA, 3Zymogenetics/BMS, Seattle, WA, USA, 4Bristol-Myers Squibb, Wallingford Center, CT,
USA, 5Bristol-Myers Squibb and Yale University School of Medicine, Wallingford, CT, USA,
6Bristol-Myers Squibb, Princeton, NJ, USA
OBJECTIVES: Flu-like symptoms (pyrexia, chills, myalgia and arthralgia) are expe-
rienced by 30%-50% of chronic hepatitis C (CHC) patients undergoing combination
interferon and ribavirin (RBV) treatment and are often cited as reasons for discon-
tinuation. To track these symptoms, the Hepatitis Physical Symptom Severity Di-
ary (HPSS-D), was developed.METHODS: Four items from the HPSS-D comprise the
Flu-Like Symptom Index (Index): fever, chills, muscle aches/pain, and joint pain.
Response options ranged from 0 (no symptoms) to 10 (worst symptom/problem)
over the past 24 hours. The diary was completed for 7 consecutive days at baseline
and weeks 4, 8 and 12. Data from two Phase 2b studies of treatment-naïve patients
comparing pegIFNalpha2a/RBV (peg-alfa) to peg-INF Lambda/RBV (peg-lambda)
and peg-alfa to peg-alfa and direct acting antiviral were combined. Measurement
properties were assessed. Mean and change scores and proportions of patients
reporting flu-like symptoms were calculated. RESULTS: Measurement properties
of the Index were supported with test-retest ICC value of 0.85, Cronbach’s alpha
range: 0.73-0.81, low to moderate construct validity [range: 0.23-0.63], and demon-
strated known groups validity (based on physician-reported flu symptoms). Re-
sponsiveness coefficients suggested a small to medium effect (SES0.40;
SRM0.39). MIDs were 2.5-3.0 points. Mean Index scores at week 12 for the peg-alfa
group (N36) increased from baseline by 2.39  4.95 versus 0.83  5.05 for peg-
lambda patients (N26). The percentage reporting any flu-like symptoms was sig-
nificantly higher for peg-alfa (75%) versus peg-lambda patients (27%) at week 12,
(p0.001), despite similar baseline rates. Fewer peg-lambda versus peg-alfa pa-
tients (50% versus 82%) experienced clinically significant worsening of flu-like
symptoms. CONCLUSIONS: PRO measures are important parameters to gauge pa-
tients’ experience with treatment, providing systematic assessment of treatment
benefit and side effects. This new Flu-Like Symptom Index from the HPSS-D dem-
onstrated adequate measurement properties and detected lower intensity and fre-
quency of flu-like symptoms for peg-lambda versus peg-alfa patients.
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OBJECTIVES: To develop and validate a clinically useful instrument for assessing
the impact of gastrointestinal symptoms (GI) on the health-related quality of life
(HRQoL) of solid organ transplant (SOT) patients (kidney, liver, heart or lung).
METHODS: Two phases: the Mypaciente-1 study was an epidemiological, cross-
sectional, multicentre study in which the SIGIT-QoL® questionnaire (17 items) was
developed and its reliability, feasibility and validity (content and construct) were
proven. At second, an observational, prospective, multicentre study, the Mypaci-
ente-2, was implemented to assess the test-retest reliability and the sensitivity to
change of the SIGIT-QoL®. SOT patients aged18, who had received the graft 3-24
months before and suffering from GI, were evaluate at baseline, 1-2 weeks and 3
months after baseline. Data recorded: age, sex, SOT type, acute allograft rejection
(AAR), GI etiology, Clinical and Patient global Impression scale (CGI-SI&GI and PGI-
SI&GI) and the SIGIT-QoL® (range: 0-maximum impact to 68-minimum disrup-
tion). Intraclass correlation (ICC), differences between baseline and last visit (Wil-
coxon test), effect size (Cohen’s d), the minimal important difference –MID- (using
CGI & PGI as anchors in General Linear Models) and the cut-off score (ROC analysis)
were calculated. RESULTS: In the Mypaciente-2 study 277 SOT patients (61.4%
males) were included. Mean age (SD) was 52.69(11.65) years, time since transplan-
tation was 12.31(6.74) months and 22.4% suffered AAR. At baseline, SIGIT-QoL®
scores: 51.21(11.25) showed an impact on patients’ HRQoL that diminished 3
months later: 57.40(8.38;p0.001). SIGIT-QoL® test-retest reliability was adequate
(ICC0.740-0.895). A high-moderate effect size (d-0.590) was found. Moreover,
MID of 4.2 points in total scores were found (F4,22316.917,p0.001 and
F4,22425.138,p0.001). Finally, a cut-off point (55.00 points) was estimated
(AUC0.846,p0.001; sensitivity0.793; specificity0.713; negative likelihood ra-
tio0.290; positive likelihood ratio2.762). CONCLUSIONS: The SIGIT-QoL® is a
feasible (average completion time lower than 6.5 minutes), reliable and valid in-
strument for assessing the impact of GI symptoms on SOT patients.
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OBJECTIVES: Hepatitis C virus (HCV) infection is associated with fatigue, anxiety,
and depression. Little is known, however, about the effect of sleep disturbances on
health-related quality of life (HRQoL), and what factors are associated with such
disturbances. METHODS: This study is based on data from the EU National Health
and Wellness Survey (N57,805), a cross-sectional database representative of the
adult EU population. Patients who reported being diagnosed with HCV by a physi-
cian and provided household income and body weight information were included
for analysis (N301). Patients who reported experiencing insomnia or sleep diffi-
culty symptoms in the past year (n135) were compared with patients who did not
experience such symptoms (n166). Sleep group membership was predicted with
a logistic regression model, while mental and physical HRQoL (SF-12) were pre-
dicted with multiple regression models. Covariates included age, gender, marital
status, education, income, employment, BMI, exercise and smoking habits, alcohol
use, and physician diagnosed HIV/AIDS, hepatitis B, anxiety disorder, and
depression. RESULTS: HCV patients with sleep disturbances were significantly
younger (48.8 vs. 51.7) and more likely to be diagnosed with HIV/AIDS (8.1% vs.
2.4%), an anxiety disorder (56.3% vs. 22.9%), and depression (48.9% vs. 10.8%)
(ps0.05) than patients with no sleep disturbances. After controlling for potential
confounders, anxiety disorder (OR2.2) and depression (OR5.1) were the only
significant predictors of sleep disturbances (ps0.05). SF-12 mental HRQoL scores
were significantly associated with age (b0.2), anxiety disorder (b -5.7), depres-
sion (b -5.9), and sleep disturbances (b -5.1, ps0.05). SF-12 physical HRQoL
scores, however, were not associated with sleep disturbance. CONCLUSIONS: De-
spite the strong association of anxiety disorder and depression with sleep distur-
bances among HCV-infected individuals, sleep disturbances had an independent
and significant effect on mental HRQoL in this population. The results suggest
effective treatment of disturbed sleep may improve the quality of life of HCV pa-
tients.
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OBJECTIVES: Active ulcerative colitis (UC) negatively impacts patients’ health-re-
lated quality of life (HRQoL); thus a fundamental goal of treatment is to achieve and
maintain disease remission. The current analysis examines how long-term main-
tenance treatment with a multi-matrix (MMX) oral formulation of mesalamine
impacted disease-specific HRQoL in patients with quiescent UC. METHODS: This
analysis examined the 12-month maintenance phase of a two-phase, multicenter,
open-label study, during which patients with quiescent UC at baseline received
MMX mesalamine 2.4 g/day QD. Disease-specific HRQoL was measured at baseline,
six-month, and twelve-month (endpoint) visits using the Shortened Inflammatory
Bowel Disease Questionnaire (SIBDQ), which measures 4 domains: bowel symp-
toms, systemic symptoms, emotional function and social function. Changes in
SIBDQ domains and total score over time were assessed using repeated-measures
analysis of variance. Correspondence between disease-specific HRQoL and disease
activity was assessed using analysis of covariance to compare SIBDQ scores at
month 12 between clinically recurrent and non-recurrent patients while control-
ling for age, gender, and BMI. RESULTS: Data were collected from 203, 144, and 157
patients at baseline, 6-month, and 12-month/early withdrawal visits, respectively.
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